Our Mission
To Bring Those Tracking the Weight Loss Market The Latest Industry News and Company Developments, Marketdata Commentary and Opinions. To Provide An Ongoing Forum for Discussion and Feedback for Those Working in The Weight Loss Field.
The Most Comprehensive Study About The U.S. Weight Loss Market–Since 1989
The U.S. Weight Loss & Diet Control Market
March 2023 427 Pages 160 tables/charts Price: $1,995
The $75 billion U.S. weight loss market grew nearly 15% last year from the depressed level of 2020. Most segments of the market have recovered from the Covid-19 pandemic and recession. The big story of 2022 has been the soaring demand for new obesity drugs such as Wegovy and Saxenda, with more new drugs coming soon. The market may be entering a new era of medical approaches. Even Weight Watchers is now providing a medical plan.
The frozen diet entrees market and diet soft drinks have shown surprising strength, but the health clubs industry was devasted by the pandemic and emerges as a smaller sector. Supply chain disruptions affected the MLM market for meal replacements into 2021 and 2022, tamping down growth for Herbalife and Medifast. The ranks of commercial weight loss centers have been thinned out, and chains had to pivot to virtual client meetings and drop shipping of
products.
Do-it-yourself plans still abound as consumers use free diet & fitness apps. Many untapped niches still exist. This is a completely revised and updated analysis of Marketdata’s best-selling biennial study about the U.S. weight loss market. This is the most comprehensive investigation of the U.S. weight loss market published by anyone worldwide.
Covered… dollar value & growth rates of all major weight loss market segments (early 1980s to 2022 and 2023 & 2027 forecasts), latest market trends and developments, status reports for: diet soft drinks, artificial sweeteners, health clubs, commercial diet center chains, multi-level marketing diet plans, retail meal replacements & weight loss supplements, medical programs (weight loss surgery, MDs, hospitals/clinic programs, Rx diet drugs, bariatricians, VLCD programs), low-cal frozen entrees, and the diet books & exercise DVDs market.
New for this edition:
- Effects of the Pandemic on operations & revenues for all market segments, analysis of the recovery
- How dieter behavior changed with the pandemic
- The skyrocketing market for Rx obesity drugs and MD programs
- 2022 market performance, 2023 & 2027 Forecasts
- The most popular diets today
- Ranking of the leading competitor companies
- Outlook for the 2023 diet season
- Why MLM is a major force in meal replacements sales, tough year in 2022
- The franchising slowdown.
Also included: 34-year revenue analysis of the market through past recessions and fad diet cycles, comprehensive dieter demographics, weight loss center franchising, and extensive national/state commercial centers’ operating ratios. Rankings & revenues of top commercial chains, brand sales, and a Reference Directory. Contains 34 in-depth competitor profiles for: Weight Watchers, Jenny Craig, NutriSystem, Medifast, Herbalife, Noom, Slim-Fast, Atkins Nutritionals, HMR, Optifast, Robard, Lindora Clinics, Slimgenics, Ideal Protein, Profile by Sanford, BeachBody, Metabolic Research, Smart For Life, Medi-Weightloss, Centers for Medical Weight Loss, Nuviva, JumptStart MD, Dr. G’s, more.
Report also sold by individual chapters at lower price. $99 Overview available.
Latest News
Nearly all patients quit weight loss shots within two years, study finds
July 11, 2024 An article by Endpoints.com cited a study that found that only about 15% of people who began taking GLP-1 drugs such as Wegovy stuck with them after two years, according to a new analysis by pharmacy benefit manager Prime Therapeutics. Prime, which is owned by a group of Blue Cross Blue Shield plans, didn’t dig into why patients quit the drugs. Pat Gleason, Prime’s assistant vice president of health outcomes who led the study, said in an
Employers and Insurers Push Back on GLP-1 Drugs Coverage
June 13, 2024 Just 33% of employers and health plans cover the drugs for obesity, according to a report published Tuesday by consultant firm Pharmaceutical Strategies Group. The biggest reason? The drugs’ high costs. “Affordability is the main challenge, and we have seen a few employers offer coverage, then pull back after they evaluated the spend they incurred,” Renee Rayburg, the firm’s vice president of clinical strategy, told Endpoints News in an email. Some organizations have stopped covering the drugs
Kroger’s Little Clinics Adds GLP-1 Drugs To Its Weight Loss Program
June 11, 2024 Kroger Health’s The Little Clinic LLC is announcing a renewed approach to its weight management program, offering a holistic and personalized approach to professional medical support and education. When medically appropriate, patients will be able to explore medical treatment, including GLP-1s such as Wegovy, Zepabound and others as part of their weight loss journey. Starting at $99 per visit, the program is available in-person and via telehealth and The Little Clinic accepts insurance plans to help cover
Most weight loss drug users quit before seeing benefits
May 22, 2024 A majority of patients taking weight loss drugs discontinue use of their medication before reaching a clinically meaningful health benefit, according to new research published May 21 by the Blue Cross Blue Shield Association. The study was conducted by Blue Health Intelligence and is based on national pharmacy and medical claims data from nearly 170,000 commercial insurance members, the largest study of its kind to date. Members included in the study were prescribed Wegovy or Saxenda between July
Marketdata weight loss reports have been quoted by..
